论文部分内容阅读
口服普萘洛尔已成为治疗婴幼儿血管瘤(IH)的一线药物。目前尚无普萘洛尔成功治疗其他脉管异常的报道,该文旨在研究普萘洛尔治疗其他脉管异常病变的频率和原因。回顾2008-2017年作者所在脉管异常治疗中心接受普萘洛尔治疗的患儿,结合病史、影像资料和病理结果,多学科分析得出诊断。与之前诊断比较,将患者分为3组,第1组,患儿与之前诊断的IH相符;第2组,患儿之前误诊为IH;第3组,患儿之前诊断为非IH脉
Oral propranolol has become the first line of treatment for infantile hemangiomas (IH). There is no report of successful treatment of other vascular abnormalities with propranolol. This article aims to study the frequency and causes of propranolol in the treatment of other abnormal vascular lesions. The authors reviewed the children who received propranolol treatment in the vascular abnormality treatment center of the author’s office from 2008 to 2017. Combined with medical history, imaging data, and pathological findings, multidisciplinary analysis led to diagnosis. Compared with the previous diagnosis, the patients were divided into 3 groups. In the first group, the children were consistent with the previously diagnosed IH. In the second group, the children were misdiagnosed as IH. In the third group, the children were diagnosed as non-IH.